At the #STATSummit, Adam Feuerstein asks Kailera CEO Ron Renaud about what it’s like to buy drug candidates from China, where Kailera got its portfolio:

Is the market for obesity drugs saturated with Lilly and Novo offerings? Kailera CEO Ron Renaud, speaking at the #STATSummit, thinks not:

Harvard researcher Paola Arlotta speaks at the #STATSummit about the progress made on organoids and the probability that there will be a major breakthrough on brain diseases using organoids in the next 10 years:

Michael D. Green, a postdoctoral fellow at Johns Hopkins School of Public Health and one of the plaintiffs suing the NIH over alleged freedom of speech infringements, talks about what it was like to have to change the direction of his research to abide by Trump administration rules. #STATSummit

The ACLU, Protect Democracy, and other organizations are representing researchers in a class action lawsuit alleging the NIH is infringing on their freedom of speech by screening grants for certain words and viewpoints when making funding decisions. We hear from one of the plaintiffs. #STATSummit

As the Trump administration pushes alternatives to animal research, one scientist is growing brain tissue in a dish and exploring the ethical questions it raises — including whether lab-grown organoids could have human rights. #STATSummit

If we want to lower drug prices, the biotech industry needs to take a hard look at which drugs make it out of Phase 1 trials and which ones don’t, says Institute for Clinical and Economic Review CEO Sarah Emond. #STATSummit

David Schenkein, general partner and life sciences lead at GV, and Jamil Beg, partner at SV Health Investors, talk about the competitive threats China poses to U.S. biotech companies. #STATSummit

Something Ventured
Venture capitalists have a well-worn playbook in the drug industry. But the rise of the Chinese biotech industry and the potential of AI are scrambling it. We hear how three top investors are responding to change. #STATSummit

Chris Deacon, an insurance whistleblower, tells the #STATSummit that employers buying insurance have what she calls the “congressman problem.”

Nearly half of Americans get health insurance through work, but rising costs are straining businesses and trapping workers in jobs they don’t want. We hear from a whistleblower who risked everything to challenge the system and urge employers to act. #STATSummit

Really excited for this afternoon of day two of the #STATsummit, where I get to nerd out on brain organoids with one of the field’s pioneers, Paola Arlotta.

As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university. MIT president worries about a ‘serious drought’ in curiosity-driven research. #STATSummit https://bit.ly/3VJ4YqA

Stephen Hoge of Moderna talks about the partnership with Merck that produced an mRNA vaccine for cancer. #STATSummit

You may know about the DOJ’s Health Care Fraud Unit and its high-profile convictions. But at #STATSummit, we learn how the unit is expanding, using technology, and targeting health care companies in Boston and Silicon Valley.

Former FDA leaders see signs the agency is returning to “the basics.” Their warning: The chaos may have eased, but rebuilding its workforce and public credibility will take years. www.statnews.com/2026/10/14/f... via @statnews.com @chelseacirruzzo.bsky.social #STATSummit

Congressman @repauchincloss.bsky.social pulling no punches at the #statsummit:

Cory Anderson balances his time between communities of Plain People and his position as an assistant professor of public health at the Penn State College of Medicine. He speaks at the #STATSummit about reimagining our idea of Amish and Mennonite vaccine hesitancy.

New: After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward. #STATSummit

www.statnews.com/2026/10/15/m...

Rep. Jake Auchincloss (D-Mass.) says when it comes to competing in biotech globally, Washington needs to “fix itself and worry less about what China is doing.” #STATSummit